chronic kidney disease Archives - MedCity News https://medcitynews.com/tag/chronic-kidney-disease/ Healthcare technology news, life science current events Wed, 27 Sep 2023 17:56:12 +0000 en-US hourly 1 https://wordpress.org/?v=6.3.1 https://medcitynews.com/uploads/2021/03/cropped-mblue-32x32.png chronic kidney disease Archives - MedCity News https://medcitynews.com/tag/chronic-kidney-disease/ 32 32 40682243 Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust? https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/ https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/#respond Thu, 21 Sep 2023 20:30:59 +0000 https://medcitynews.com/?p=649473 Urinary system, bladder, kidney

Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.

]]>
https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/feed/ 0 649473
Strive Health, Oak Street Health Strike Kidney Care Partnership https://medcitynews.com/2023/08/chronic-kidney-disease-partnership-value-based-care/ https://medcitynews.com/2023/08/chronic-kidney-disease-partnership-value-based-care/#respond Wed, 30 Aug 2023 20:57:32 +0000 https://medcitynews.com/?p=647112

Kidney care company Strive Health announced last week that it is collaborating with primary care company Oak Street Health to serve Medicare members with stage 4 chronic kidney disease and end-stage kidney disease.

]]>
https://medcitynews.com/2023/08/chronic-kidney-disease-partnership-value-based-care/feed/ 0 647112
Humana Taps Interwell Health for Kidney Care https://medcitynews.com/2023/08/humana-chronic-kidney-disease/ https://medcitynews.com/2023/08/humana-chronic-kidney-disease/#respond Thu, 24 Aug 2023 19:51:41 +0000 https://medcitynews.com/?p=646350

In a new agreement, Interwell Health will provide care to Humana Medicare Advantage HMO and PPO members with chronic kidney disease in 13 states. It will also serve patients with end-stage kidney disease across the country.

]]>
https://medcitynews.com/2023/08/humana-chronic-kidney-disease/feed/ 0 646350
Emergency Dialysis: A Crutch for Fee-For-Service Healthcare https://medcitynews.com/2023/08/emergency-dialysis-a-crutch-for-fee-for-service-healthcare/ https://medcitynews.com/2023/08/emergency-dialysis-a-crutch-for-fee-for-service-healthcare/#respond Wed, 09 Aug 2023 18:42:29 +0000 https://medcitynews.com/?p=641070

Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.

]]>
https://medcitynews.com/2023/08/emergency-dialysis-a-crutch-for-fee-for-service-healthcare/feed/ 0 641070
Signify Health Unveils Chronic Kidney Disease Evaluation https://medcitynews.com/2023/08/chronic-kidney-disease-evaluation/ https://medcitynews.com/2023/08/chronic-kidney-disease-evaluation/#respond Thu, 03 Aug 2023 22:37:21 +0000 https://medcitynews.com/?p=644043

Home care company Signify Health announced Tuesday that it added an in-home kidney health evaluation to its platform. Based on the results of the evaluation, the company can refer patients to their primary care physician or a specialist if they’re in need of further treatment.

]]>
https://medcitynews.com/2023/08/chronic-kidney-disease-evaluation/feed/ 0 644043
The Case for Automatic Surveillance during Dialysis https://medcitynews.com/2023/04/the-case-for-automatic-surveillance-during-dialysis/ https://medcitynews.com/2023/04/the-case-for-automatic-surveillance-during-dialysis/#respond Wed, 19 Apr 2023 16:13:33 +0000 https://medcitynews.com/?p=628266

This lack of monitoring is a serious problem—both for patients and for the overall healthcare system. The data show that in a typical dialysis center, each patient will suffer an average of 1.7 access blockages per year.

]]>
https://medcitynews.com/2023/04/the-case-for-automatic-surveillance-during-dialysis/feed/ 0 628266
GSK Gets FDA Nod for Drug Treating Anemia From Chronic Kidney Disease https://medcitynews.com/2023/02/gsk-gets-fda-nod-for-drug-treating-anemia-from-chronic-kidney-disease/ https://medcitynews.com/2023/02/gsk-gets-fda-nod-for-drug-treating-anemia-from-chronic-kidney-disease/#respond Thu, 02 Feb 2023 17:42:53 +0000 https://medcitynews.com/?p=622738

The FDA approved GSK drug Jesduvroq for treating anemia in patients with chronic kidney disease. The once-daily pill is the first oral medicine to pass FDA muster in this indication, giving patients a more convenient alternative to injectable anemia therapies.

]]>
https://medcitynews.com/2023/02/gsk-gets-fda-nod-for-drug-treating-anemia-from-chronic-kidney-disease/feed/ 0 622738
Lessons learned from prison and dialysis while trying to prevent the pain, loss and cost of kidney diseases https://medcitynews.com/2022/08/lessons-learned-from-prison-and-dialysis-is-there-a-path-to-prevent-the-pain-loss-and-cost-of-kidney-diseases/ https://medcitynews.com/2022/08/lessons-learned-from-prison-and-dialysis-is-there-a-path-to-prevent-the-pain-loss-and-cost-of-kidney-diseases/#respond Tue, 02 Aug 2022 13:00:51 +0000 https://medcitynews.com/?p=593597

These two health care settings provided invaluable lessons: get ahead of the curve through collaboration with other doctors, better monitoring, early referrals, and education.

]]>
https://medcitynews.com/2022/08/lessons-learned-from-prison-and-dialysis-is-there-a-path-to-prevent-the-pain-loss-and-cost-of-kidney-diseases/feed/ 0 593597
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.? https://medcitynews.com/2022/07/is-the-hif-phi-class-of-next-generation-kidney-drugs-doomed-in-the-u-s/ https://medcitynews.com/2022/07/is-the-hif-phi-class-of-next-generation-kidney-drugs-doomed-in-the-u-s/#respond Fri, 22 Jul 2022 22:41:53 +0000 https://medcitynews.com/?p=593066 Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is applying the appropriate benefit/risk assessment for new drugs intended for this population.

]]>
https://medcitynews.com/2022/07/is-the-hif-phi-class-of-next-generation-kidney-drugs-doomed-in-the-u-s/feed/ 0 593066
The medtech industry’s responsibility in addressing the socioeconomic barriers to accessing and succeeding on renal replacement therapy https://medcitynews.com/2022/07/the-medtech-industrys-responsibility-in-addressing-the-socioeconomic-barriers-to-accessing-and-succeeding-on-renal-replacement-therapy/ https://medcitynews.com/2022/07/the-medtech-industrys-responsibility-in-addressing-the-socioeconomic-barriers-to-accessing-and-succeeding-on-renal-replacement-therapy/#respond Tue, 19 Jul 2022 22:46:24 +0000 https://medcitynews.com/?p=592283

Aside from rallying for more patient-oriented reimbursement and removing the red tape involved so that providers can provide home-based dialysis care, medical device manufacturers must also offer a turnkey solution for home-based therapy that includes servicing the device in a door-to-door model.

]]>
https://medcitynews.com/2022/07/the-medtech-industrys-responsibility-in-addressing-the-socioeconomic-barriers-to-accessing-and-succeeding-on-renal-replacement-therapy/feed/ 0 592283
Claiming Akebia agreement breach, Otsuka seeks to end anemia drug pact https://medcitynews.com/2022/05/claiming-akebia-agreement-breach-otsuka-seeks-to-end-anemia-drug-pact/ https://medcitynews.com/2022/05/claiming-akebia-agreement-breach-otsuka-seeks-to-end-anemia-drug-pact/#respond Mon, 16 May 2022 16:56:54 +0000 https://medcitynews.com/?p=587612 handshake, break, deal

Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, vadadustat, and asked for another clinical trial. Otsuka alleges unspecified breaches of the agreement by Akebia, and ending the alliance early could spare it from spending hundreds of millions of dollars more on the drug.

]]>
https://medcitynews.com/2022/05/claiming-akebia-agreement-breach-otsuka-seeks-to-end-anemia-drug-pact/feed/ 0 587612
Safety concerns sink Akebia drug for anemia from chronic kidney disease https://medcitynews.com/2022/03/safety-concerns-sink-akebia-drug-for-anemia-from-chronic-kidney-disease/ https://medcitynews.com/2022/03/safety-concerns-sink-akebia-drug-for-anemia-from-chronic-kidney-disease/#respond Fri, 01 Apr 2022 03:28:52 +0000 https://medcitynews.com/?p=580911

The FDA rejected Akebia Therapeutics drug vadadustat as a treatment for anemia caused by chronic kidney disease. According to the biotech, the agency cited safety concerns and asked for another clinical trial to show that the pill’s benefits outweigh its risks.

]]>
https://medcitynews.com/2022/03/safety-concerns-sink-akebia-drug-for-anemia-from-chronic-kidney-disease/feed/ 0 580911
Executives at new InterWell Health, formed by 3-way merger, want to turn kidney care on its head https://medcitynews.com/2022/03/executives-at-new-interwell-health-formed-by-3-way-merger-want-to-turn-kidney-care-on-its-head/ https://medcitynews.com/2022/03/executives-at-new-interwell-health-formed-by-3-way-merger-want-to-turn-kidney-care-on-its-head/#respond Wed, 23 Mar 2022 23:27:43 +0000 https://medcitynews.com/?p=579144

The new organization combining InterWell, Fresenius Health Partners and Cricket Health is valued at $2.4 billion with a total addressable market of $170 billion, more than $6 billion of medical costs under management, and over 100,000 covered lives, according to the combined company.

]]>
https://medcitynews.com/2022/03/executives-at-new-interwell-health-formed-by-3-way-merger-want-to-turn-kidney-care-on-its-head/feed/ 0 579144
How to ensure Medicare’s kidney care contracting model succeeds — and transform treatment https://medcitynews.com/2022/03/how-to-ensure-medicares-kidney-care-contracting-model-succeeds-and-transform-treatment/ https://medcitynews.com/2022/03/how-to-ensure-medicares-kidney-care-contracting-model-succeeds-and-transform-treatment/#respond Tue, 22 Mar 2022 23:07:06 +0000 https://medcitynews.com/?p=575850

Medicare’s Comprehensive Kidney Care Contracting model spotlights the importance of proactive, coordinated kidney care. It’s critical for nephrology practices to start incorporating this patient-centric approach and consider more than just immediate kidney concerns.

]]>
https://medcitynews.com/2022/03/how-to-ensure-medicares-kidney-care-contracting-model-succeeds-and-transform-treatment/feed/ 0 575850
FDA rejects Reata Pharma chronic kidney disease drug; new trial needed https://medcitynews.com/2022/02/fda-rejects-reata-pharma-chronic-kidney-disease-drug-new-trial-needed/ https://medcitynews.com/2022/02/fda-rejects-reata-pharma-chronic-kidney-disease-drug-new-trial-needed/#respond Sun, 27 Feb 2022 17:19:27 +0000 https://medcitynews.com/?p=573837

The FDA told Reata that the clinical data do not show that the drug, bardoxolone, slows the progression of the loss of kidney function in patients who have the rare disease Alport syndrome. The regulatory decision follows an FDA advisory committee vote recommending against approval of the small molecule drug.

]]>
https://medcitynews.com/2022/02/fda-rejects-reata-pharma-chronic-kidney-disease-drug-new-trial-needed/feed/ 0 573837
The cavalry has arrived for the kidney care revolution: Policymakers, start-ups join physicians’ longstanding fight to transform a troubled industry https://medcitynews.com/2022/02/the-calvary-has-arrived-for-the-kidney-care-revolution-policymakers-start-ups-join-physicians-longstanding-fight-to-transform-a-troubled-industry/ https://medcitynews.com/2022/02/the-calvary-has-arrived-for-the-kidney-care-revolution-policymakers-start-ups-join-physicians-longstanding-fight-to-transform-a-troubled-industry/#respond Sun, 27 Feb 2022 15:00:51 +0000 https://medcitynews.com/?p=565443

To combat challenges facing the industry, both policymakers and entrepreneurs have been working on complementary strategies to help primary care physicians, nephrologists and other care team members disrupt the status quo.

]]>
https://medcitynews.com/2022/02/the-calvary-has-arrived-for-the-kidney-care-revolution-policymakers-start-ups-join-physicians-longstanding-fight-to-transform-a-troubled-industry/feed/ 0 565443
Regenerative med biotech ProKidney inks merger to get $825M for CKD cell therapy https://medcitynews.com/2022/01/regenerative-med-biotech-prokidney-inks-825m-merger-to-back-ckd-cell-therapy/ https://medcitynews.com/2022/01/regenerative-med-biotech-prokidney-inks-825m-merger-to-back-ckd-cell-therapy/#respond Wed, 19 Jan 2022 00:55:44 +0000 https://medcitynews.com/?p=566488

ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.

]]>
https://medcitynews.com/2022/01/regenerative-med-biotech-prokidney-inks-825m-merger-to-back-ckd-cell-therapy/feed/ 0 566488
CSL shakes off pandemic woes, diversifies with $11.7B Vifor Pharma acquisition https://medcitynews.com/2021/12/csl-shakes-off-pandemic-woes-diversifies-with-11-7b-vifor-pharma-acquisition/ https://medcitynews.com/2021/12/csl-shakes-off-pandemic-woes-diversifies-with-11-7b-vifor-pharma-acquisition/#respond Wed, 15 Dec 2021 00:12:21 +0000 https://medcitynews.com/?p=562242

CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. In acquiring Vifor Pharma, CSL not only diversifies, it also expands its presence in the fast-growing nephrology market.

]]>
https://medcitynews.com/2021/12/csl-shakes-off-pandemic-woes-diversifies-with-11-7b-vifor-pharma-acquisition/feed/ 0 562242
Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions https://medcitynews.com/2021/11/vifor-pharma-adds-to-chronic-kidney-disease-lineup-with-pair-of-acquisitions/ https://medcitynews.com/2021/11/vifor-pharma-adds-to-chronic-kidney-disease-lineup-with-pair-of-acquisitions/#respond Mon, 22 Nov 2021 17:30:40 +0000 https://medcitynews.com/?p=559586 Urinary system, bladder, kidney

Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a blood vessel complication affecting some chronic kidney disease patients. Both biotechs are in clinical trials with their respective lead drug candidates.

]]>
https://medcitynews.com/2021/11/vifor-pharma-adds-to-chronic-kidney-disease-lineup-with-pair-of-acquisitions/feed/ 0 559586
Why there is great need for additional treatments to manage hyperphosphatemia in patients with CKD on dialysis https://medcitynews.com/2021/10/why-there-is-great-need-for-additional-treatments-to-manage-hyperphosphatemia-in-patients-with-ckd-on-dialysis/ https://medcitynews.com/2021/10/why-there-is-great-need-for-additional-treatments-to-manage-hyperphosphatemia-in-patients-with-ckd-on-dialysis/#respond Tue, 05 Oct 2021 18:00:40 +0000 https://medcitynews.com/?p=552056

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially address.

]]>
https://medcitynews.com/2021/10/why-there-is-great-need-for-additional-treatments-to-manage-hyperphosphatemia-in-patients-with-ckd-on-dialysis/feed/ 0 552056
FDA approves first drug for severe itching in chronic kidney disease patients https://medcitynews.com/2021/08/fda-approves-first-drug-for-severe-itching-in-chronic-kidney-disease-patients/ https://medcitynews.com/2021/08/fda-approves-first-drug-for-severe-itching-in-chronic-kidney-disease-patients/#respond Tue, 24 Aug 2021 23:00:50 +0000 https://medcitynews.com/?p=546326

Chronic kidney disease patients who experience pruritus after dialysis can now get relief from the first FDA-approved treatment for the condition. Cara Therapeutics received the FDA’s green light for its injectable drug, Korsuva.

]]>
https://medcitynews.com/2021/08/fda-approves-first-drug-for-severe-itching-in-chronic-kidney-disease-patients/feed/ 0 546326
FDA turns down Ardelyx’s chronic kidney disease drug and asks for another trial https://medcitynews.com/2021/07/fda-turns-down-ardelyxs-chronic-kidney-disease-drug-and-asks-for-another-trial/ https://medcitynews.com/2021/07/fda-turns-down-ardelyxs-chronic-kidney-disease-drug-and-asks-for-another-trial/#respond Thu, 29 Jul 2021 22:23:59 +0000 https://medcitynews.com/?p=542660 Urinary system, bladder, kidney

Ardelyx drug tenapanor was rejected by the FDA as a treatment for a complication experienced by chronic kidney disease patients. The regulatory decision came two weeks after the company received an FDA letter citing deficiencies in the drug application.

]]>
https://medcitynews.com/2021/07/fda-turns-down-ardelyxs-chronic-kidney-disease-drug-and-asks-for-another-trial/feed/ 0 542660
Bayer kidney disease drug gets FDA nod, pitting it against AstraZeneca, J&J meds https://medcitynews.com/2021/07/bayer-kidney-disease-drug-gets-fda-nod-pitting-it-against-astrazeneca-jj-meds/ https://medcitynews.com/2021/07/bayer-kidney-disease-drug-gets-fda-nod-pitting-it-against-astrazeneca-jj-meds/#respond Sun, 11 Jul 2021 12:01:21 +0000 https://medcitynews.com/?p=539570

The FDA has approved Bayer’s Kerendia to treat chronic kidney disease in patients with type 2 diabetes. The drug is the first in its class, giving the pharma giant an alternative way to compete against medicines already marketed by AstraZeneca and Johnson & Johnson.

]]>
https://medcitynews.com/2021/07/bayer-kidney-disease-drug-gets-fda-nod-pitting-it-against-astrazeneca-jj-meds/feed/ 0 539570
In-home kidney care startup Monogram raises $160M https://medcitynews.com/2021/06/in-home-kidney-care-startup-monogram-raises-160m/ https://medcitynews.com/2021/06/in-home-kidney-care-startup-monogram-raises-160m/#respond Thu, 10 Jun 2021 11:45:36 +0000 https://medcitynews.com/?p=534686

Monogram Health, a Tennessee-based startup that offers in-home care services for patients with chronic kidney disease raised $160 million in funding. The startup plans to use the funds to fuel its expansion across the U.S.

]]>
https://medcitynews.com/2021/06/in-home-kidney-care-startup-monogram-raises-160m/feed/ 0 534686
Congress: Pass the RAISE Act to address health disparities, advance health Equity in kidney care https://medcitynews.com/2021/06/congress-pass-the-raise-act-to-address-health-disparities-advance-health-equity-in-kidney-care/ https://medcitynews.com/2021/06/congress-pass-the-raise-act-to-address-health-disparities-advance-health-equity-in-kidney-care/#respond Tue, 01 Jun 2021 11:00:15 +0000 https://medcitynews.com/?p=532502

As the nation continues to reckon with disparities in health, we have a real opportunity to remove barriers to proper kidney care.

]]>
https://medcitynews.com/2021/06/congress-pass-the-raise-act-to-address-health-disparities-advance-health-equity-in-kidney-care/feed/ 0 532502
Startup targets orphan kidney disease with former Merck drug https://medcitynews.com/2021/01/startup-targets-orphan-kidney-disease-with-former-merck-drug/ https://medcitynews.com/2021/01/startup-targets-orphan-kidney-disease-with-former-merck-drug/#respond Mon, 25 Jan 2021 21:08:42 +0000 https://medcitynews.com/?p=511124 money, dollar

Vera Therapeutics licensed the drug candidate after analysis of earlier trials revealed its promise. Boosted by $80 million in Series C funding, the company hopes to launch a phase 2B trial this year.

]]>
https://medcitynews.com/2021/01/startup-targets-orphan-kidney-disease-with-former-merck-drug/feed/ 0 511124
AI predicts better kidney care https://medcitynews.com/2021/01/ai-predicts-better-kidney-care/ https://medcitynews.com/2021/01/ai-predicts-better-kidney-care/#respond Tue, 05 Jan 2021 16:30:53 +0000 https://medcitynews.com/?p=509438

AI models offer an early look into who might develop kidney disease, who would benefit from early intervention, and the risk of further complications without a change in course. However, it is worth taking a close look to ensure any bias or gaps are addressed.  

]]>
https://medcitynews.com/2021/01/ai-predicts-better-kidney-care/feed/ 0 509438
CVS launches clinical trial for at-home hemodialysis device https://medcitynews.com/2019/07/cvs-launches-clinical-trial-for-at-home-hemodialysis-device/ https://medcitynews.com/2019/07/cvs-launches-clinical-trial-for-at-home-hemodialysis-device/#respond Wed, 17 Jul 2019 17:45:00 +0000 https://medcitynews.com/?p=464570

CVS Health’s new HemoCare device would open up the at-home market for hemodialysis, which uses an artificial kidney device to perform the procedure and has traditionally been difficult to provide outside of a clinical setting.

]]>
https://medcitynews.com/2019/07/cvs-launches-clinical-trial-for-at-home-hemodialysis-device/feed/ 0 464570
President Trump aims to upend existing kidney care models through executive order https://medcitynews.com/2019/07/president-trump-aims-to-upend-existing-kidney-care-models-through-executive-order/ https://medcitynews.com/2019/07/president-trump-aims-to-upend-existing-kidney-care-models-through-executive-order/#respond Thu, 11 Jul 2019 00:06:38 +0000 https://medcitynews.com/?p=463985

The executive order is focused on increasing the supply of kidneys available for transplants, improving prevention and treatment of chronic kidney disease and pushing the majority of dialysis patients to get their treatment through less-costly and more convenient home care.

]]>
https://medcitynews.com/2019/07/president-trump-aims-to-upend-existing-kidney-care-models-through-executive-order/feed/ 0 463985
Healthy.io raises $18M to bring smartphone urinalysis tech to U.S. https://medcitynews.com/2019/02/healthy-io-raises-18m-to-bring-smartphone-urinalysis-tech-to-u-s/ https://medcitynews.com/2019/02/healthy-io-raises-18m-to-bring-smartphone-urinalysis-tech-to-u-s/#respond Wed, 06 Feb 2019 00:39:16 +0000 https://medcitynews.com/?p=450243

Healthy.io’s urinalysis testing kit – dubbed Dip.io – uses disposable strips and cups in conjunction with a smartphone camera to read and interpret results.

]]>
https://medcitynews.com/2019/02/healthy-io-raises-18m-to-bring-smartphone-urinalysis-tech-to-u-s/feed/ 0 450243